Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 1, 2025Open Access

In Silico discovery and design of molecular glues as a new strategy for development of non-peptidic, small-molecule agonists of GLP-1 receptor

View Full Paper
Ask AI
Bookmark
Share

Authors

LTLiang TangHZHaiyan Zhao

Discussion

Loading...

Member takes

Overview

Virtual screening identifies molecular glues that enhance GLP-1 receptor signaling, suggesting new small-molecule agonists may improve treatment for type 2 diabetes and obesity.

Key Points

  • Molecular glues can enhance the assembly of GLP-1R and G-protein, leading to potential allosteric activation.
  • Virtual screening identified candidate compounds with binding affinities comparable to peptide-based drugs, like orforglipron.
  • The approach utilizes a new strategy to design small-molecule GLP-1R agonists, addressing limitations of existing peptidic medications.
  • Molecular hybridization has resulted in compounds with improved binding properties, expanding therapeutic options for metabolic disorders.

Cite This Study

Tang et al. (2025) studied this question.

synapsesocial.com/papers/68dd9537fe798ba2fc499786https://doi.org/10.26434/chemrxiv-2025-k2gjf
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Structural basis for chemotype diversity in small molecule GLP-1 receptor agonist drug discovery2025
  2. 2Innovative molecules and delivery technologies enabling the future of GLP-1-based therapies2025
  3. 3Exploring Conformational Transitions in Biased and Balanced Ligand Binding of GLP-1R2025
  4. 4Computational assessment of the dimeric incretin GLP-1cpGLP-1 reveals the structural bases for its activity2025
  5. 5AI-Driven De Novo Design of Ultra Long-Acting GLP-1 Receptor Agonists.2025